Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07FUP
|
||||
| Former ID |
DIB003567
|
||||
| Drug Name |
Dupilumab
|
||||
| Synonyms |
REGN-668; REGN-668); SAR-231893; Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis
|
||||
| Drug Type |
Antibody
|
||||
| Company |
Regeneron Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-4 receptor alpha chain | Target Info | [532365] | ||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| IL4-mediated signaling events | |||||
| WikiPathways | Inflammatory Response Pathway | ||||
| IL-4 Signaling Pathway | |||||
| References | |||||
| Ref 524442 | ClinicalTrials.gov (NCT01949311) Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis. U.S. National Institutes of Health. | ||||
| Ref 542567 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7574). | ||||
| Ref 889446 | Drugs@FDA (Edaravone) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.